Market Overview

Sequenom Says Genetic Test Predicts Progression Risk

Related SQNM
Sequenom Labs Reports Expanded Int'l Noninvasive Prenatal Testing Service with VisibiliT Test
UPDATE: Jefferies Resumes Coverage On Sequenom On Revised Revenue/EPS Forecasts

Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced its wholly-owned subsidiary, Sequenom Center for Molecular Medicine (Sequenom CMM), presented results from a study of its RetnaGene AMD laboratory-developed test to predict risk of disease progression during the 2012 Joint Meeting of the American Academy of Ophthalmology and the Asia-Pacific Academy of Ophthalmology in Chicago.

Posted-In: News FDA

 

Related Articles (SQNM)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters